Infection
Conditions
Interventions
Trade Name: Zyvoxid
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: LINEZOLID
Other descriptive name: LINEZOLID
Sponsors
Helena Barrasa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Admitted to the intensive care unit. Diagnosis of sepsis. Need to linezolid because of suspected infection due to multiresistant gram positive cocci Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10
Exclusion criteria
Exclusion criteria: Pregnancy. Age <18 years. Severe renal failure
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): To compare the risk of overexposure of two different dosage regimen of linezolid;Timepoint(s) of evaluation of this end point: 4 days | — |
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To characterize the pharmacokinetics of linezolid when administered by continuous infusion;Secondary Objective: - To calculate the parameters related to the efficacy and toxicity - To cCompare the results with those obtained after conventional administration;Primary end point(s): To compare the efficacy of two different dosage regimen of linezolid;Timepoint(s) of evaluation of this end point: 4 days | — |
Countries
Spain
Contacts
Public ContactUnidad de Cuidados Intensivos
Osakidetza
Outcome results
None listed